When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ZGNX - Zogenix's Fintepla successful in third pivotal study in severe type of epilepsy
Zogenix Inc.
Zogenix (NASDAQ:ZGNX)announces positive results from a third Phase 3 clinical trial, Study 3, evaluating Fintepla (fenfluramine) for the treatment of seizures associated with Dravet syndrome, a rare and severe type of childhood epilepsy. The results were consistent with the results in Studies 1&2.
More news on: Zogenix, Inc., Healthcare stocks news,